Articles tagged "CD20"

2015 American Transplant Congress
Excellent Outcomes of Prophylactic Rituximab Administration With Plasmapheresis in Kidney Transplant Recipients With Focal Segmental Glomerulosclerosis
M. Okumi,¹ Y. Miyauchi,² T. Yagisawa,¹ K. Unagami,¹ D. Toki,¹ K. Omoto,¹ H. Ishida,¹ K. Tanabe.¹
¹Urology, Tokyo Women's Medical University, Shinjuku, Tokyo, Japan; ²Urology, Ehime University, Matsuyama, Ehime, Japan.
[Background]The estimated recurrence rate of focal segmental glomerulosclerosis (FSGS) after kidney transplantation is approximately 30%. Relapse occurring immediately after transplantation is refractory to treatment and…
2015 American Transplant Congress
Retrospective Cohort Study Concerning Efficacy and Safety of Bortezomib in Combination With Or Without Rituximab in Antibody Mediated Rejection in Renal Transplant Recipients
M. Duerr, N. Lachmann, K. Budde, J. Waiser.
Charité Universitätsmedizin Berlin, Department of Nephrology, Berlin, Germany.
Treatment of antibody-mediated rejection (AMR) in renal transplant (tx) patients (pts) is still challenging and long-term outcome remains unsatisfying. Because plasma cells (PCs) are crucial…
2015 American Transplant Congress
Results of ABO Incompatible Liver Transplantation Using a Simplified Protocol at a Single Institution
J. Lee,¹ J. Lee,¹ J. Lee,² M. Kim,¹ M. Ju,¹ G. Choi,¹ J. Choi,¹ S. Kim,¹ D. Joo.¹
¹Department of Surgery, Yonsei University College of Medicine, Seoul, Republic of Korea; ²Department of Surgery, CHA Bundang Medical Center, Bundang, Republic of Korea.
BackgroundABO incompatible (ABOi) living donor liver transplantation (LDLT) has become a feasible option for patients with end-stage liver disease due to development of various desensitization…
2015 American Transplant Congress
The Best Regimen With Rituximab for ABO-Incompatible Living Donor Liver Transplantation
H. Egawa,¹ K. Umeshita,² S. Uemoto.³
¹Surgery, Tokyo Women's Medical University, Tokyo, Japan; ²Osaka University, Suita, Japan; ³Kyoto University, Kyoto, Japan.
Rituximab made a great progress on outcomes of ABO-incompatible living donor liver transplantation (ABO-I LDLT). Although Japanese multicenter study group published efficacy and safety of…
2015 American Transplant Congress
Mononuclear Cell Infiltrates Characterization in Scar Tissue from a Bilateral Forearm Transplant Patient: Findings to Think
J. Furuzawa-Carballeda,¹ M. Iglesias,² J. Alberu,³ A. Gamboa,⁴ P. Butrón,² M. Morán-Romero,² Y. Esquivel.¹
¹Immunology, INCMNSZ, Mexico City, Mexico; ²Plastic Surgery, INCMNSZ, Mexico, Mexico; ³Transplants, INCMNSZ, Mexico, Mexico; ⁴Pathology, INCMNSZ, Mexico City, Mexico.
Herein we report the cell infiltrating pattern in scar tissue resected at the junction of the VCA and the tissue corresponding to the recipient arm,…
2015 American Transplant Congress
Cardiac Xenotransplantation: Reconstituted B Cells After Rituxan Treatment Maintain Their Repertoire But Have a Muted Response to Xenoantigens
A. Singh,¹ P. Corcoran,¹ B. Lewis,² M. Thomas,² D. Ayers,³ K. Horvath,¹ M. Mohiuddin.¹
¹CSRP/NIH/NHLBI, NIH, Bethesda, MD; ²DVR/ORS, NIH, Bethesda, MD; ³Revivicor Inc, Blacksburg, VA.
Background: Xentoranplantation (XTx) remains an option for end stage organ failure. Recently we have reported cardiac xenograft survival of over one year pig to baboon…
2015 American Transplant Congress
Incidence and Clinical Severity of Hypogammaglobulinemia (Hypo-IgG) in Highly-HLA Sensitized Patients (HS) Undergoing Desensitization (DES)
A. Vo,¹ S. Ge,² A. Petrosyan,² M. Toyoda,² J. Choi,¹ J. Kahwaji,¹ A. Peng,¹ R. Villicana,¹ S. Jordan.¹
¹Kidney Transplant, Cedars-Sinai Medical Center, LA; ²Transplant Immunology Laboratory, Cedars-Sinai Medical Center, LA, CA.
Introduction: Desensitization therapies (DES) have dramatically improved rates of transplantation among HS patients. However, antibody-reduction and B-cell/plasma cell directed therapies could have implications for humoral…
2015 American Transplant Congress
Efficacy and Safety of Desensitization Protocol Based On Rituximab Plus MMF in ABO-Incompatible Kidney Transplantation Without Splenectomy
K. Takahashi,¹ K. Saito,² S. Takahara,³ S. Fuchinoue,⁴ T. Yagisawa,⁵ A. Aikawa,⁶ Y. Watarai,⁷ N. Yoshimura,⁸ K. Tanabe,⁴ K. Morozumi,⁹ M. Shimazu.¹⁰
¹Niigata Organ Transplant Foundation, Niigata, Japan; ²Graduate School of Medical ＆ Dental Sciences, Niigata University, Niigata, Japan; ³Osaka University Graduate School of Medicine, Osaka, Japan; ⁴Tokyo Women's Medical University, Tokyo, Japan; ⁵Jichi Medical University Hospital, Tochigi, Japan; ⁶Toho University, Faculty of Medicine, Tokyo, Japan; ⁷Nagoya Daini Red Cross Hospital, Aichi, Japan; ⁸Kyoto Prefectural University of Medicine, Kyoto, Japan; ⁹Masuko Memorial Hospital, Aichi, Japan; ¹⁰Tokyo Medical University Hachioji Medical Center, Tokyo, Japan.
Purpose: An open-label, single arm, multicenter clinical study has been conducted in Japan for prospective examination of the efficacy and safety of desensitization protocol with…
2015 American Transplant Congress
Pre-Transplant Desensitization Protocol and Cancer Risk in Kidney Transplantation
I. Revuelta,^1,2,3 R. Ferreira,¹ C. Canha,¹ P. Piselli,⁴ D. Verdirosi,⁴ V. Tubita,² E. De Sousa,¹ F. Diekmann,^1,2,3 M. Lozano,^2,5 J. Cid,⁵ E. Palou,⁶ J. Martorell,⁶ A. Alcaraz,⁷ D. Serraino,⁸ F. Oppenheimer,^1,2,3 J. Campistol.^1,2,3
¹Renal Transplant Unit, Department of Nephrology and Kidney Transplant, Hospital Clinic, Barcelona, Spain; ²IDIBAPS, Barcelona, Spain; ³REDinREN. Carlos III Royal Institute. Ministry of Health, Madrid, Spain; ⁴Dipartamento di Epidemiologia e Ricerca Pre-Clinica, INMI “L. Spallanzani” IRCCC, Rome, Italy; ⁵Hemotherapy and Hemostasis, Hospital Clinic, Barcelona, Spain; ⁶Department of Immunology, Hospital Clinic, Barcelona, Spain; ⁷Department of Urology, Hospital Clinic, Barcelona, Spain; ⁸IRCCS Centro di Riferimento Oncologico, Aviano, Italy.
Introduction: Desensitization (DS) in kidney transplant is a current therapy for all cause of incompatible living donor kidney transplants (LDKT). The impact in cancer risk…